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Abstract
Background: Hemodynamic congestion is an increase in left ventricular diastolic pressure (LVEDP) without clinical symptoms and 
signs of congestion. Current acute heart failure (AHF) treatment goals only focused on improving clinical congestion. The purpose of 
this study was to investigate whether hemodynamic congestion measured by NT-proBNP level and ePCWP at hospital discharge could 
predict short term clinical outcomes in AHF patients.
Methods: This prospective cohort study was conducted at dr. Saiful Anwar General Hospital Malang from January to July 2018. All 
patients got AHF treatment according to the 2016 ESC guidelines for heart failure. All patients were discharged without symptoms and 
signs of clinical congestion. Hemodynamic congestion at hospital discharge was defined as failure of treatment during hospitalization 
to achieve NT-proBNP reduction of > 30% and/or ePCWP at hospital discharge > 16 mmHg. NT-proBNP level and ePCWP were 
measured at 0-12 hours after hospital admisssion and at hospital discharge. ePCWP was measured using echocardiography. The clinical 
outcomes assessed were AHF rehospitalization and cardiovascular mortality within 30 days after hospitral discharge. Subgroup analysis 
was performed to determine treatment regimen that are effective in improving hemodynamic congestion.
Results: A total of 33 AHF patients were included in this study. 48% patients were discharged with hemodynamic congestion and 52% 
patients discharged without hemodynamic congestion. Patients with hemodynamic congestion at hospital discharge showed a higher 
rehospitalization within 30 days (8 [50%] vs 1 [5.9%]; P = 0.007). Mortality within 30 days in both groups did not show a significant 
difference (2 [12.5%] vs 0 [0%]; P = 0.277). Treatment regimen of optimal dose of ACEI/ARB, β-blocker, and diuretic was correlated 
with improvement of hemodynamic congestion (P = 0.026; r = 0.454), NT-proBNP reduction of > 66% (P = 0.02; r = 0.574), and 
achievement of ePCWP < 16 mmHg (P = 0.013; r = 0.493) at hospital discharge in HFrEF patients.
Conclusion: Hemodynamic congestion assessed using NT-proBNP level and ePCWP at hospital discharge increased 30 day 
rehospitalization in AHF patients. In HFrEF, improvements of hemodynamic congestion can be achieved by giving the treatment regimen 
of optimal dose of ACEI/ARB, β-blocker, and diuretic.
(Indonesian J Cardiol. 2019;40:290-300)
Keyword: Acute heart failure, hemodynamic congestion, NT-proBNP, ePCWP
Department of Cardiology and Vascular Medicine Faculty of 
Medicine, Universitas Brawijaya - Dr. Saiful Anwar General 
Hospital Malang
Correspondence:
Yoga Waranugraha, MD, FIHA
Department of Cardiology and Vascular Medicine
Faculty of Medicine, Universitas Brawijaya
dr. Saiful Anwar General Hospital Malang
E-mail: mr.waranugraha@gmail.com
doi: 10.30701/ijc.v40i3.805
Introduction
Heart failure is a global pandemic problem,1 affecting more than 37.7 million people worldwide.  According to the RISKESDAS 2013, the prevalence of heart failure 
in Indonesia was 0.3%.3  Patients with heart failure 
experience various kinds of clinical symptoms that 
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can reduce the quality of life.2 Heart failure imposes 
a huge economic burden, estimated at 108 billion 
US dollar per year.  AHF refers to rapid onset or 
worsening of symptoms and/or signs of heart failure. It 
is a life-threatening medical condition requiring urgent 
evaluation and treatment, typically leading to urgent 
hospital admission.5  Despite therapeutic advances, the 
prognosis of acute heart failure is poor, with in-hospital 
mortality ranging from 4% to 7%, 60- to 90-day 
mortality ranging from 7% to 11%, and 60- to 90-day 
rehospitalization from 25% to 30%.6
 Hemodynamic congestion is defined as high 
ventricular diastolic pressures without overt clinical 
signs. Clinical congestion may resolve with treatment 
but hemodynamic congestion may persist, leading to 
a high risk of rehospitalization.7,8 Data from studies 
with implantable hemodynamic monitors have 
confirmed that chronically elevated filling pressures or 
hemodynamic congestion are associated with increased 
risk of future events.9 Hemodynamic congestion could 
be assessed by increasing levels of NT-proBNP and 
PCWP.10,11 Several studies have shown that the relative 
NT-proBNP reduction of < 30% at hospital discharge is 
a significant predictor of mortality and rehospitalization 
in AHF patients.12,13 In AHF patients, achieving PCWP 
< 16 mmHg at hospital discharge provides a better 
1-year survival rate.14,15 PCWP can be estimated non-
invasively using echocardiography.16,17 The purpose of 
this study was to investigate whether hemodynamic 
congestion measured by NT-proBNP level and ePCWP 
at hospital discharge could predict short term clinical 
outcomes in AHF patients.
 
Methods
Study Design and Populations
We conducted a prospective cohort study in dr. Saiful 
Anwar General Hospital Malang from January to June 
2018. This research is a part of joint research by multi 
department entitled “Additive Value of Monitoring Non 
Invasive Cardiac Hemodynamic and Total Body Water 
Content in Critical Care Patients Outcomes in Acute 
Medicine Department from ER Admission to Discharge”. 
This study involved AHF patients aged 40 years or more. 
Exclusion criteria included pregnancy, acute coronary 
syndrome, patients on invasive mechanical ventilation, 
cardiac arrest, cardiac tamponade, congenital heart 
disease, stenosis lesion of the heart valve, patients with 
mechanical or bioprostetic valves, left atrial myxoma, 
thrombus in the left atrium, thrombus in pulmonary 
vein, patient with cardiac implantable electronic devices 
(Pacemaker, ICD, or CRT), patient discharged from 
hospital without ACEI/ARB and/or β-blocker, patients 
discharged from hospital with clinical congestion, 
pulmonary embolism, pulmonary hypertension 
other than due to dysfunction left ventricle, COPD, 
pneumothorax, CKD, hyperthyroidism, stroke/TIA, 
malignancy, and terminal disease.
 We performed measurement of NT-proBNP and 
ePCWP in AHF who came to the emergency room 
(ER) of dr. Saiful Anwar General Hospital in 0-12 hours 
after hospital admission. All patients received AHF 
therapy based on the 2016 ESC guidelines for heart 
failure.5 All patients are discharged from the hospital 
without symptoms and signs of clinical congestion. The 
second measurement of NT-proBNP and ePCWP was 
performed at hospital discharge. Patients were classified 
into 2 groups based on the presence of hemodynamic 
congestion at hospital discharge. Hemodynamic 
congestion at hospital discharge was defined as failure 
of treatment during hospitalization to achieve NT-
proBNP reduction of > 30% and/or ePCWP at hospital 
discharge ≥ 16 mmHg. The primary endpoints were 
AHF rehospitalization and cardiovascular mortality 
within 30 days after hospital discharge. Subgroup 
analysis was performed to determine the effective 
therapeutic regimen to achieve secondary endpoints 
which included hemodynamic congestion, NT-proBNP 
level, and ePCWP.
BT-pro BNP and ePCWP Measurements
NT-proBNP level was obtained from venous 
blood and processed using the sandwich-type 
electrochemiluminescence sensor method. ePCWP 
was measured using echocardiography. ePCWP was 
calculated using the formula ePCWP = 1.24 x (E/e') + 
1.9, e' = (lateral e' + septal e') / 2.18 For patients with 
single transmitral flow due to sinus tachycardia, ePCWP 
was calculated using the formula ePCWP = 1,47 x (E/e') 
+ 1,5.19 Whereas for patients with atrial fibrillation, 
ePCWP was calculated using the formula ePCWP = 
0.821 x (E/e') + 6.489.17 In this study we used General 
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Table 1. Baseline characteristics of AHF patients at hospital admission
Hemodynamic congestion (+) Hemodynamic congestion (-)
P-value
n = 16 n = 17
Age, years, mean + SD 57,50±12,03 66,47±12,25 0,034
Men (%) 10(62,5%) 8(47,1%) 0,373
NYHA IV functional class (%) 16(100%) 17(100%) -
Dyspnea (%) 16(100%) 17(100%) -
Orthopnea (%) 15(93,8%) 11(64,7%) 0,085
PND (%) 10(62,5%) 11(64,7%) 0,895
GCS, mean + SD 15,00±0,00 15,00±0,00 1
SBP, mmHg, mean + SD 144,63±37,17 144,12±33,86 0,986
DBP, mmHg, mean + SD 85,88±17,58 85,00±15,33 0,828
MAP, mmHg, mean + SD 107,00±25,92 105,18±20,69 0,9
HR, bpm, mean + SD 104,50±20,59 106,00±15,14 0,626
RR, tpm, mean + SD 31,25±4,31 30,00±3,67 0,355
S3 (%) 4(25%) 3(17,6%) 0,688
Rhales (%) 16(100%) 17(100%) -
JVP cmH2O, mean + SD 9,19±1,79 9,18±0,88 0,573
Asites (%) 6(37,5%) 1(5,9%) 0,039
Hepatomegaly (%) 6(37,5%) 6(35,3%) 0,895
Leg edema (%) 10(62,5%) 2(11,8%) 0,002
Atrial Fibrillation (%) 4(25%) 3(17,6%) 0,688
Supraventricular arrhythmia (%) 1(6,3%) 0(0%) 0,485
Ventricular arrhythmia (%) 4(25%) 3(17.6%) 0,688
CTR, %, mean + SD 72,94±5,95 69,71±4,82 0,116
Interstitial congestion (%) 15(93,8%) 17(100%) 0,485
Alveolar congestion (%) 3(18,8%) 2(11,8%) 0,656
Pleural effusion (%) 2(12,5%) 3(17,6%) 1
Hemoglobin, g/dl, mean + SD 13,46±2,62 13,71±15,4 0,719
NT-proBNP, pg/ml, mean + SD 17547,75±12178,83 13286,06±12788,50 0,366
Ureum, mg/dl, mean + SD 48,04±20,31 50,73±28,51 1
Creatinine, mg/dl, mean + SD 1,39±0,54 1,33±0,64 0,614
eGFR, ml/min/1.73 m2, mean + SD 60,99±33,67 61,5±28,29 0,54
AST, mg/dl, mean + SD 42,50±49,63 28,18±16,16 0,159
ALT, mg/dl, mean + SD 33,38±45,34 35,12±36,18 0,287
Oxygen supplementation, %, mean + SD 77,06±27,54 69,41±28,29 0,299
PH, mean + SD 7,33±0,08 7,39±0,10 0,097
PaCO2, mmHg, mean + SD 35,43±11,76 32,67±12,81 0,387
PaO2, mmHg, mean + SD 112,36±44,34 114,65±28,35 0,494
HCO3-, mmol/l, mean + SD 18,85±4,81 19,59±4,18 0,54
Base excess, mmol/l, mean + SD -8,56±3,55 -6,08±4,43 0,077
SaO2, %, mean + SD 95,85±3,82 97,69±1,54 0,97
RWMA (%) 13(81,3%) 15(88,2%) 0,656
EF Biplane, %, mean + SD 34,31±11,88 35,88±8,89 0,54
E/e', mean + SD 18,42±3,05 19,41±2,99 0,46
ePCWP, mmHg mean + SD 24,13±4,09 25,35±3,90 0,302
LVEDD, cm, mean + SD 5,98±1,15 5,61±0,88 0,517
LVESD, cm, mean + SD 4,89±1,26 4,69±0,97 0,639
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electronic Vivid e and Vivid 5 echocardiography 
machines. Echocardiographic examination was 
performed by two senior cardiology and vascular 
medicine residents. The interobserver variability was 
tested using the Cohen’s Kappa test. No significant 
difference in echocardiography interpretations between 
both operators.
Statistical Analysis
Numerical variables are presented as mean ± SD. 
Categorical variables are presented as frequencies and 
percentages. The comparison between 2 numerical 
variables was tested using the Mann Whitney test. 
The comparison between 2 categorical variables was 
tested using the Chi square test or Fisher's test. AHF 
rehospitalization and cardiovascular mortality within 
30 days after hospital discharge were presented in 
the Kaplan-Meier curve. The cut off piont of some 
variables was tested using the ROC curve. The 
relationship between 2 nominal variables is tested using 
the contingency coefficient test. P value ≤ 0.05 was 
considered statistically significant. All statistical analyses 
were performed using IBM SPSS Statistics 21. 
Results
Baseline Characteristics
A total of 33 AHF patients with NYHA IV functional 
class were included in this study. 48% of patients 
were discharged from the hospital with hemodynamic 
congestion and 52% of patients were discharged from 
the hospital without hemodynamic congestion. In 
general, the basic characteristics of the two groups were 
not different. Patients discharged from the hospital with 
hemodynamic congestion were younger than patients 
discharged from the hospital without hemodynamic 
congestion (57.50 ± 12.03 vs 66.47 ± 12.25; P = 0.034). 
Ascites and limb edema at hospital admission were more 
prevalent in patients discharged from the hospital with 
hemodynamic congestion than in patients discharged 
from the hospital without hemodynamic congestion (6 
(37.5%) vs 1 (5.9%); P = 0.039 and 10 (62.5%) vs 2 
(11.8%); P = 0.002 respectively) (Table 1). The length of 
stay between the two groups was not different (Table 2). 
All patients were discharged from the hospital without 
clinical congestion. The treatment regimen at hospital 
discharge between the two groups were not different. 
Clinical outcomes
Patients were followed for 30 days after hospital discharge. 
30 day cardiovascular mortality in both groups was not 
significantly different (2 [12.5%] vs 0 [0%]; P=0,277). 
Patient with hemodynamic congestion at hospital 
discharge showed a higher 30 day rehospitalization than 
patient patient without hemodynamic congestion at 
hospital discharge (8 [50%] vs 1 [5.9%]; P = 0.007). 
Survival analysis using Kaplan-Meier curve showed 
significant differences in 30 day rehospitalization 
after hospital discharge (Log rank, P = 0.004) but 
not mortality (Log rank, P = 0.138) (Picture 1). After 
hospital discharge, daily drug dose regimen between the 
two groups were not different generally. Patients with 
hemodynamic congestion received a lower daily dose 
of furosemide than patients without hemodynamic 
congestion (25.33 + 9.15 mg vs. 33.33 + 9.75 mg; P = 
0.031) after hospital discharge (Table 4).
Subgroup Analysis
NT-proBNP is a well-known prognostic biomarker for 
AHF rehospitalization, but its value greatly varies among 
individuals. The ROC curve showed that the NT-
LAVI, ml/m2 mean + SD 50,56±15,54 49,94±14,63 0,957
Mitral regurgitation (%) 14(87,5%) 14(82,4%) 1
PND = Paroxysmal nocturnal dyspnea; GCS = Glasgow coma scale; SBP = Systolic blood pressure; DBP = Diastolic blood 
pressure; MAP = Mean arterial pressure; HR: heart rate; RR: respiratory rate; S3 = third heart sound; JVP = jugular venous 
pressure; CTR = cardiothoracic ratio; eGFR = Estimated glomerular filtration rate; AST = Aspartate aminotransferase; ALT = 
Alanine aminotransferase; PaCO2 = partial pressure of carbon dioxide in the arterial blood; PaO2 = partial pressure of oxygen 
in the arterial blood; HCO3- = bicarbonate; RWMA = regional wall motion abnormality; EF = Ejection fraction; E/e’ =  ratio 
between early mitral inflow velocity and mitral annular early diastolic velocity; LVEDD = left ventricular end systolic diameter; 
LAVI: left atrial volume index.
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proBNP reduction during in-hospital treatment (cut off 
66%; sensitivity 75%; specificity 76%; AUC 0.755; P 
= 0.032) was better than single NT-proBNP value at 
hospital discharge (cut off 2813 pg/mL; sensitivity 75%; 
specificity 68%; AUC 0.755; P = 0.032) in predicting 
AHF rehospitalization (Picture 2).
 We tried to find out the correlation between 
heart failure drug therapy regimen during in-hospital 
treatment with the achievement of secondary endpoints 
which included hemodynamic congestion, NT-
proBNP reduction of > 66%, and ePCWP <16 mmHg 
at the hospital discharge. In the HFmrEF patients, 
administration of treatment regimen of optimal dose of 
ACEI/ARB, β-blocker, and diuretic was not associated 
with secondary endpoints (Table 5). Administration 
of treatment regimen of optimal dose of ACEI/ARB, 
β-blocker, and diuretic was associated with improvement 
of hemodynamic congestion (P = 0.026; r = 0.454), 
NT-proBNP reduction of > 66% (P = 0.02; r = 0.574), 
and achievement of ePCWP < 16 mmHg (P = 0.013; 
r = 0.493) at hospital discharge in the HFrEF patients 
(Table 6). 
Discussion
In this study, we tried to combine biomarker and 
hemodynamic parameters measured noninvasively 
in assessing hemodynamic congestion. We used cut 
off point according to the results of several previous 
studies.12,13,14,15 Previous studies used pulmonary 
artery catheter to measure PCWP.14,15 No previous 
study used ePCWP measured by echocardiography as a 
hemodynamic parameter in AHF. 
 Hemodynamic congestion occurs within a few days 
or weeks before clinical congestion.20 In our study, the 
30 day rehospitalization was higher in patient with 
hemodynamic congestion at hospital discharge. Patient 
with hemodynamic congestion suffered from symptoms 
of clinical congestion in few days or weeks after 
hospital discharge. Those conditions forced them for 
urgent hospital admission. In this study, patients who 
were discharged from the hospital with hemodynamic 
congestion received lower dose of furosemide. We were 
unable to intervene the therapeutic regimen which given 
by the physician in charge because our study design 
Table 2. Treatment during hospitalization
Hemodynamic congestion (+) Hemodynamic congestion (-)
P-value
n = 16 n = 17
O2 supplementation (%) 16(100%) 17(100%) -
NIV (%) 2(12,5%) 1(5,9%) 0,601
Inotropic (%) 2(12,5%) 2(11,8%) 1
Diuretic (%) 16(100%) 17(100%) -
Nitrate (%) 6(37,5%) 8(47,1%) 0,579
ACEI/ARB (%) 16(100%) 17(100%) -
CCB (%) 3(18,8%) 4(23,5%) 1
MRA (%) 9(56,3%) 14(82,4%) 0,104
OAC/NOAC (%) 4(25%) 3(17,6%) 0,688
Antiplatelet (%) 12(75%) 15(88,2%) 0,398
Statin (%) 14(87,5%) 16(94,1%) 0,601
β-blocker (%) 16(100%) 17(100%) -
Digoxin (%) 2(12%) 4(23,5%) 0,656
OAD (%) 1(6,3%) 3(17,6%) 0,601
Insulin (%) 2(12,5%) 1(5,9%) 0,601
Length of stay, day, mean + SD 5,63±2,92 5,29±2,54 0,798
NIV = Non invasive ventilation; ACEI = Angiotensin converting enzyme inhibitor; ARB = Angiotensin receptor blocker; CCB 
= Calcium channel blocker; MRA = Mineralocorticoid receptor antagonist; OAC = Oral anticoagulant; NOAC = Novel oral 
anticoagulant; OAD = Oral anti diabetes.
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was an observational study. The decision of physician 
in charge to discharge the patient was made based on 
the absence of the clinical congestion according to the 
2016 ESC guidelines for heart failure.5 We performed 
measurement of NT-proBNP level and ePCWP after the 
patients were decided to be discharged from the hospital 
by the physician in charge. Hemodynamic congestion 
and inadequate dose of furosemide could accelerate the 
occurrence of clinical congestion and rehospitalization. 
Moreover, there were several confounding factors which 
were difficult to be managed that could exacerbate AHF 
and rehospitalization such as acute coronary syndromes, 
non-compliance with medications, arrhythmia, or 
infection. In this study, cardiovascular mortality in 
both groups was not significantly different because the 
duration of follow-up is shorter than several previous 
Table 3. Symptoms, signs, and medical treatment at hospital discharge
Hemodynamic congestion (+) Hemodynamic congestion (-)
P-value
n = 16 n = 17
Dyspnea (%) 0% 0% -
Orthopnea (%) 0% 0% -
PND (%) 0% 0% -
GCS, mean + SD 15,00±0,00 15,00±0,00 1
SBP, mmHg, mean + SD 122,13±16,72 117,41±19,21 0,37
DBP, mmHg, mean + SD 76,75±11,93 71,29±6,20 0,09
MAP, mmHg, mean + SD 92,63±11,83 86,59±9,25 0,111
HR, bpm, mean + SD 78,81±6,38 74,76±6,60 0,112
RR, tpm, mean + SD 19,50±0,89 19,24±0,97 0,381
S3 (%) 0% 0% -
Rhales (%) 0% 0% -
JVP cmH2O, mean + SD 6,44±0,63 5,64±0,61 0,002
Ascites (%) 0% 0% -
Hepatomegaly (%) 0% 0% -
Leg edema (%) 0% 0% -
Diuretic (%) 15 (93,8%) 15 (88,2%) 1
Nitrate (%) 8(50%) 6(35,3%) 0,393
ACEI/ARB (%) 16(100%) 17(100%) -
CCB (%) 3(18,8%) 4(23,5%) 1
MRA (%) 9(56,3%) 14(82,4%) 0,141
OAC/NOAC (%) 4(25%) 3(17,6%) 0,688
Antiplatelet (%) 11(68,8%) 15(88,2%) 0,225
Statin (%) 14(87,5%) 16(94,1%) 0,601
β-blocker (%) 16(100%) 17(100%) -
Digoxin (%) 2(12,5%) 4(23,5%) 0,656
OAD (%) 1(6,3%) 3(17,6%) 0,601
Insulin (%) 2(12,5%) 1(5,9%) 0,601
PND = Paroxysmal nocturnal dyspnea; GCS = Glasgow coma scale; SBP = Systolic blood pressure; DBP = Diastolic 
blood pressure; MAP = Mean arterial pressure; HR: heart rate; RR: respiratory rate; S3: third heart sound; JVP: 
jugular venous pressure; ACEI = Angiotensin converting enzyme inhibitor; ARB = Angiotensin receptor blocker; 
CCB = Calcium channel blocker; MRA = Mineralocorticoid receptor antagonist; OAC = Oral anticoagulant; NOAC 
= Novel oral anticoagulant; OAD = Oral anti diabetes
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studies which ranged from 180 days to 1 year.12,13,14,15, 
 Our study supports the evidence that the failure 
in improving the hemodynamic congestion in AHF is 
associated with an increased risk of rehospitalization 
within 30 days after hospital discharge. Therefore, we 
conducted subgroup analysis to search for the treatment 
regimen to achieve secondary endpoints which included 
haemodynamic congestion, NT-proBNP reduction> 
66%, and PCWP achievement <16 when the patient 
discharged from the hospital. Patients were grouped 
into HFmrEF group and HFrEF group. 
 In HFmrEF patients, treatment regimen 
of optimal dose of ACEI/ARB, β-blocker, and 
diuretic was not correlated with improvement in 
hemodynamic congestion, NT-proBNP reduction of 
> 66%, and achievement of ePCWP < 16 mmHg at 
hospital discharge. These results may be caused by the 
heterogeneous pathophysiologic mechanism in HFpEF 
and HFmrEF.22,23 In the clinical trials and/or daily 
clinical practice, only a few patients with HFpEF and 
HFmrEF received ACEI/ARB, β-blocker, and diuretic 
compared to HFrEF patients.24,25,26  There is no 
effective treatment for reducing morbidity or mortality 
in HFpEF or HfmrEF patients.27 Neuro-hormonal 
antagonists (ACEIs, ARBs, MRAs, and β-blockers) 
have been shown to improve survival in patients with 
HFrEF and are recommended for the treatment of 
every patient with HFrEF, unless contraindicated or not 
tolerated. Initiation and up-titration disease-modifying 
pharmacological therapy should be done immediately. 
In case of worsening of chronic HFrEF, every attempt 
should be made to continue evidence-based, disease-
modifying therapies, in the absence of haemodynamic 
instability or contra-indications.5 In HFrEF patients, 
treatment regimen of optimal dose of ACEI/ARB, 
β-blocker, and diuretic was correlated with improvement 
in hemodynamic congestion, NT-proBNP reduction of 
> 66%, and achievement of ePCWP < 16 mmHg at 
hospital discharge. In this study, all patients received 
β-blocker during hospitalization after they had not 
shown clinical congestion and had previously received 
ACEI/ARB and diuretic. β-blocker up-titration 
also performed during hospitalization. In this study, 
β-blocker up-titration was faster than the guideline 
recommendations5 or several previous studies.28,29,30 
Our study supports the evidence that β-blocker 
initiation and up-titration during hospitalization are 
save for AHF patients as long as the clinical congestion 
has been resolved and the patients received optimal dose 
of ACEI/ARB and diuretics previously.
 Our study has several limitations. First, single center 
study and the small number of samples cannot describe 
the real world conditions. Second, the short follow-
up period makes it possible to provide biased results. 
Third, there were several confounding factors which 
were difficult to be managed that could exacerbate 
AHF and rehospitalization. Our study may be the first 
study using hemodynamic congestion measured by NT-
proBNP level and ePCWP as the predictors of short-
term clinical outcomes in AHF patients. We used very 
strict exclusion criteria to rule out comorbidities which 
can affect the result. 
Table 4. Daily dose of the heart failure drugs after hospital discharge
Drugs
Hemodynamic congestion (+) Hemodynamic congestion (-)
P-value
n = 16 n = 17
Furosemide mg, mean + SD 25,33+9,15 33,33+9,75 0,031
Nitrat mg , mean + SD 15,00+0,00 18,33+6,61 0,197
Ramipril mg, mean + SD 10,00+0,00 10,00+0,00 1
Lisinopril mg, mean + SD 20,00+0,00 20,00+0,00 1
Valsartan mg, mean + SD 192,00+121,33 240,00+80,00 0,536
Candesartan mg, mean + SD 8,00+0,00 16,00+0,00 0,157
Spironolactone mg, mean + SD 25,00+0,00 25,00+0,00 1
Bisoprolol mg, mean + SD 2,50+0,79 2,35+0,41 0,707
Digoxin mg, mean + SD 0,25+0,00 0,25+0,00 1
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Conclusion
Hemodynamic congestion assessed using NT-proBNP 
level and ePCWP at hospital discharge increased 30 
day rehospitalization in AHF patients. Hemodynamic 
congestion can be considered as a therapeutic target 
in AHF patients during hospitalization. In HFrEF, 
improvements of hemodynamic congestion can be 
achieved by giving the treatment regimen of optimal 
dose of ACEI/ARB, β-blocker, and diuretic. 
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List of Abbreviations
ACEI = Angiotensin converting enzyme inhibitor
ARB = Angiotensin receptor blocker
AHF = Acute heart failure
AUC = Area under the curve
CRT = Cardiac resynchronization therapy
CKD = Chronic kidney disease
COPD = Chronic obstructive pulmonary disease
ePCWP = Estimated pulmonary capillary wedge 
pressure
Table 5. Correlation between treatment regimen and the achievement of secondary endpoints in HFmrEF
Optimal dose of ACEI/ARB  + β-blocker + diuretic
r P-value
No Yes Total
NT-proBNP reduction of > 66%
No 2(40%) 2(22,2%) 4(28,6%)
0,185 0,48
Yes 3(60%) 7(77,8%) 10(71,4%)
PCWP <16 mmHg
No 2(40%) 3(33,3%) 5(35,7%)
0,067 0,803
Yes 3(60%) 6(66,7%) 9(64,3%)
Hemodynamic congestion
No 2(20%) 7(77,8%) 9(64,3%)
0,353 0,158
Yes 3(60%) 2(22,2%) 5(35,7%)
ACEI = Angiotensin converting enzyme inhibitor; ARB = Angiotensin receptor blocker; ePCWP = Estimated pulmonary 
capillary wedge pressure; NT-proBN P= N-terminal pro B-type natriuretic peptide; HFmrEF = Heart failure with midrange 
ejection fraction
Table 6. Correlation between treatment regimen and the achievement of secondary endpoints in HfrEF
Optimal dose of ACEI/ARB  + β-blocker + diuretic
r P-value
No Yes Total
NT-proBNP reduction of > 66%
No 5(100%) 3(21,4%) 8(42,1%)
0,574 0,02
Yes 0(0%) 11(78,6%) 11(57,9%)
PCWP <16 mmHg
No 5(100%) 5(35,7%) 10(52,6%)
0,493 0,013
Yes 0(0%) 9(64,3%) 9(47,4%)
Hemodynamic congestion
No 0(0%) 8(57,1%) 8(42,1%)
0,454 0,026
Yes 5(100%) 6(42,9%) 11(57,9%)
ACEI = Angiotensin converting enzyme inhibitor; ARB = Angiotensin receptor blocker; ePCWP = Estimated pulmonary 
capillary wedge pressure; NT-proBNP = N-terminal pro B-type natriuretic peptide; HFmrEF = Heart failure with reduced 
ejection fraction
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Figure 1. Kaplan-Meier Curve of 30 day cardiovascular mortality (A) and AHF rehospitalization (B)
Figure 2. Receiver operating characteristic (ROC) to determine the NT-proBNP cut off. Single NT-proBNP value at hospital 
discharge (A) and NT-proBNP reduction during in-hospital treatment (B)
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ER = Emergency room
ESC = European society of cardiology
HFmrEF = Heart failure with midrange ejection fraction
HFrEF = Heart failure with reduced ejection fraction
ICD = Implantable cardioverter defibrillator
MRA = Mineralocorticoid receptor antagonist
NT-proBNP = N-terminal pro B-type natriuretic 
peptide
NYHA = New York heart association
PCWP = Pulmonary capillary wedge pressure
RISKESDAS = Riset kesehatan dasar
ROC = Receiver operating characteristic
TIA = Transient ischemic attack
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